US FDA accepts NDA for once-monthly aripiprazole
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review Otsuka Pharmaceutical's NDA for a once-monthly depot formulation of its atypical antipsychotic, aripiprazole (Abilify), for the maintenance treatment of adult patients with schizophrenia.